Related Experiment Video

Updated: Dec 26, 2025

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
08:34

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

1.1K

Polydeoxyribonucleotide Exerts Therapeutic Effect by Increasing VEGF and Inhibiting Inflammatory Cytokines in

Sung-Eun Kim1, Il-Gyu Ko1, Jun-Jang Jin1

  • 1Department of Physiology, College of Medicine, Kyung Hee University, Seoul, Republic of Korea.

Biomed Research International
|March 10, 2020
PubMed

Insights

Polydeoxyribonucleotide (PDRN) effectively treats ischemic colitis in rats. This salmon sperm extract reduces inflammation and tissue damage by enhancing adenosine A2A receptor (A2AR) and vascular endothelial growth factor (VEGF) expression.

Area of Science:

  • Gastroenterology
  • Pharmacology
  • Molecular Biology

Background:

  • Ischemic colitis stems from insufficient colon blood supply.
  • Polydeoxyribonucleotide (PDRN), derived from salmon sperm, exhibits anti-inflammatory and anti-ischemic properties via adenosine A2A receptor (A2AR) activation.
  • The therapeutic potential of PDRN in ischemic colitis warrants investigation.

Purpose of the Study:

  • To evaluate the therapeutic effectiveness of PDRN in a rat model of ischemic colitis.
  • To elucidate the molecular mechanisms underlying PDRN's action in this condition.

Main Methods:

  • Ischemic colitis was induced in rats via selective devascularization.
  • Skin temperature, colonic mucosal damage, and collagen deposition were assessed.
  • Western blot analysis was used to measure A2AR, VEGF, COX-2, TNF-α, IL-1β, IL-6, Bax, Bcl-2, and ERK1/2 expression.
  • Hematoxylin and eosin (H&E) and Masson trichrome staining were performed.

Main Results:

  • Ischemic colitis rats exhibited increased skin temperature, mucosal damage, and collagen deposition.
  • Expressions of inflammatory cytokines (TNF-α, IL-1β, IL-6) and COX-2 were upregulated.
  • Apoptosis increased, indicated by a decreased Bcl-2/Bax ratio and suppressed p-ERK1/2.
  • PDRN treatment alleviated mucosal damage, reduced inflammatory markers and COX-2, and inhibited apoptosis.
  • PDRN enhanced A2AR and VEGF expression in ischemic colitis rats.

Conclusions:

  • PDRN demonstrates significant therapeutic efficacy in treating ischemic colitis.
  • PDRN acts by upregulating A2AR and VEGF, subsequently inhibiting inflammatory cytokines and COX-2.
  • PDRN offers a promising therapeutic strategy for ischemic colitis by modulating key molecular pathways.

More Related Videos

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.7K
Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies09:08

Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies

Published on: June 2, 2021

2.0K

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
383
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
385
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
399
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
773
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
980
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
356